83. Cancer Chemother Pharmacol. 2018 Apr;81(4):791-796. doi:10.1007/s00280-018-3555-2. Epub 2018 Mar 1.A novel way to manage trastuzumab cardiotoxicity.Hamdan D(1)(2), Darrouzain F(3)(4), Bejan-Angoulvant T(3)(5), Isorni C(6), Zelek L(7)(8), Paintaud G(3)(4), Janin A(2)(9)(10), Bousquet G(11)(12)(13)(14).Author information: (1)Service d'Oncologie Médicale, Grand Hôpital de l'Est Francilien, 77600,Jossigny, France.(2)INSERM, U1165, 75010, Paris, France.(3)Université François-Rabelais de Tours, CNRS, GICC UMR 7292, 37000, Tours,France.(4)Service de Pharmacologie-Toxicologie, CHRU de Tours, 37000, Tours, France.(5)Service de Pharmacologie Clinique, CHRU de Tours, 37000, Tours, France.(6)Centre Hospitalier de Versailles, 78000, Versailles, France.(7)Service d'Oncologie Médicale, AP-HP-Hôpital Avicenne, 93000, Bobigny, France.(8)Université Paris 13, 93430, Villetaneuse, France.(9)Université Paris Diderot, Sorbonne Paris Cité, Laboratoire de Pathologie,UMR-S 1165, U1165, 1 Avenue Vellefaux, 75010, Paris, France.(10)AP-HP-Hôpital Saint-Louis, Laboratoire de Pathologie, 75010, Paris, France.(11)INSERM, U1165, 75010, Paris, France. guilhem.bousquet@aphp.fr.(12)Service d'Oncologie Médicale, AP-HP-Hôpital Avicenne, 93000, Bobigny, France.guilhem.bousquet@aphp.fr.(13)Université Paris 13, 93430, Villetaneuse, France. guilhem.bousquet@aphp.fr.(14)Université Paris Diderot, Sorbonne Paris Cité, Laboratoire de Pathologie,UMR-S 1165, U1165, 1 Avenue Vellefaux, 75010, Paris, France.guilhem.bousquet@aphp.fr.PURPOSE: Trastuzumab is the most widely prescribed anti-HER2 humanized monoclonalantibody. Cardiac toxicity is the only limiting toxicity of trastuzumab and it isof particular concern in patients with complete response, since the drug needs tobe stopped, with a risk of disease relapse. To date, no pharmacological data ontrastuzumab cardiotoxicity in patients have been made available. Here, we provideproof of concept, demonstrating that it was possible to preventtrastuzumab-induced cardiotoxicity by modifying the drug administration schedule.METHODS: In this paper, we report the case of a patient with metastatic breastcancer responding to trastuzumab, who developed severe cardiac toxicity twiceusing a 3-weekly regimen. Considering preclinical pharmacological data ontrastuzumab cardiotoxicity, we hypothesized that a weekly schedule of trastuzumabwith lower peaks of serum concentration could be safe while remaining efficient. With the patient's consent, we started a weekly combination of carboplatin (AUC2)and trastuzumab (2 mg/kg) with close monitoring of trastuzumab concentrations.RESULTS: We successfully controlled the disease for an additional 6 months withrelevant trough concentrations of trastuzumab of around 50 mg/L. Anotherimportant aspect is that, with this weekly schedule, we observed no cardiactoxicity, and the left ventricular ejection fraction remained stabilized, at over50%.CONCLUSIONS: Trastuzumab is the most widely prescribed anti-HER2 monoclonalantibody for the treatment of HER2 metastatic breast cancer, and it is the onlydrug that has been approved for the treatment of localized HER2 breast cancer,1-year treatment being required after surgery. In case of cardiac toxicity,particularly in women over 60 years of age, a weekly regimen with lower peaks of concentration could be an alternative to the standard 3-weekly regimen.DOI: 10.1007/s00280-018-3555-2 PMID: 29497813 